Total Payments
$15,278
2024 Payments
$1,121
Companies
28
Transactions
74
Medicare Patients
16,453
Medicare Billing
$4.3M
Payment Breakdown by Category
Consulting$8,056 (52.7%)
Other$3,870 (25.3%)
Food & Beverage$2,311 (15.1%)
Travel$763.09 (5.0%)
Education$277.29 (1.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $8,056 | 5 | 52.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,870 | 4 | 25.3% |
| Food and Beverage | $2,311 | 50 | 15.1% |
| Travel and Lodging | $763.09 | 4 | 5.0% |
| Education | $277.29 | 11 | 1.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $5,428 | 11 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,104 | 5 | $0 (2021) |
| Progenics Pharmaceuticals, Inc. | $1,980 | 1 | $0 (2021) |
| Janssen Biotech, Inc. | $1,894 | 11 | $0 (2024) |
| ARRAY BIOPHARMA INC | $1,890 | 3 | $0 (2024) |
| Exelixis Inc. | $298.95 | 2 | $0 (2024) |
| GENZYME CORPORATION | $196.50 | 2 | $0 (2024) |
| PFIZER INC. | $167.24 | 10 | $0 (2024) |
| Gilead Sciences, Inc. | $154.18 | 4 | $0 (2024) |
| AVEO Pharmaceuticals, Inc. | $144.14 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,121 | 16 | ARRAY BIOPHARMA INC ($630.00) |
| 2023 | $2,054 | 22 | ARRAY BIOPHARMA INC ($1,260) |
| 2022 | $354.46 | 8 | Janssen Biotech, Inc. ($192.69) |
| 2021 | $4,721 | 8 | Progenics Pharmaceuticals, Inc. ($1,980) |
| 2020 | $1,148 | 3 | E.R. Squibb & Sons, L.L.C. ($1,047) |
| 2019 | $234.31 | 3 | Genentech USA, Inc. ($123.26) |
| 2018 | $16.02 | 1 | Abbott Laboratories ($16.02) |
| 2017 | $5,630 | 13 | Incyte Corporation ($5,343) |
All Payment Transactions
74 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $29.35 | General |
| Category: Oncology | ||||||
| 12/20/2024 | Incyte Corporation | — | Education | Cash or cash equivalent | $84.99 | General |
| 12/09/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.05 | General |
| Category: Hematology | ||||||
| 11/12/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.69 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $13.10 | General |
| Category: Oncology | ||||||
| 08/29/2024 | Iovance Biotherapeutics, Inc. | Amtagvi (Drug) | Food and Beverage | Cash or cash equivalent | $22.68 | General |
| Category: Oncology | ||||||
| 08/09/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: ONCOLOGY | ||||||
| 06/18/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $7.98 | General |
| Category: ONCOLOGY | ||||||
| 06/04/2024 | Janssen Pharmaceuticals, Inc | RYBREVANT (Drug) | Education | In-kind items and services | $22.00 | General |
| Category: Oncology | ||||||
| 05/24/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $46.50 | General |
| Category: Oncology | ||||||
| 05/21/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $15.57 | General |
| Category: Oncology | ||||||
| 05/06/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $630.00 | General |
| Category: ONCOLOGY | ||||||
| 04/25/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $11.88 | General |
| Category: ONCOLOGY | ||||||
| 03/28/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $28.81 | General |
| Category: ONCOLOGY | ||||||
| 03/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.47 | General |
| 01/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $136.78 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/22/2023 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $630.00 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Food and Beverage | In-kind items and services | $26.73 | General |
| Category: Oncology | ||||||
| 11/13/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $26.40 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/16/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $24.68 | General |
| Category: Oncology | ||||||
| 10/09/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $7.45 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/05/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: ONCOLOGY | ||||||
| 09/19/2023 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 09/13/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $18.26 | General |
| Category: ONCOLOGY | ||||||
| 08/29/2023 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $14.61 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 87 | 4,257 | 96,325 | $5.9M | $1.1M |
| 2022 | 84 | 4,359 | 101,113 | $6.2M | $1.2M |
| 2021 | 80 | 3,935 | 93,318 | $4.5M | $927,856 |
| 2020 | 82 | 3,902 | 82,500 | $4.9M | $990,932 |
Total Patients
16,453
Total Services
373,256
Medicare Billing
$4.3M
Procedure Codes
333
All Medicare Procedures & Services
333 procedure records from CMS Medicare Utilization — Page 1 of 14
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 27 | 13,200 | $1.8M | $570,699 | 31.7% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 33 | 50 | $240,100 | $61,352 | 25.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 144 | 419 | $296,233 | $44,792 | 15.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 158 | 440 | $161,920 | $43,350 | 26.8% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 14 | 1,930 | $349,330 | $40,704 | 11.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 14 | 2,100 | $136,800 | $36,656 | 26.8% |
| 78816 | Nuclear medicine study whole body with ct scan | Office | 2023 | 16 | 29 | $142,941 | $35,636 | 24.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 252 | 500 | $125,000 | $33,071 | 26.5% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 16 | 12,390 | $247,800 | $29,067 | 11.7% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 13 | 288 | $388,224 | $23,682 | 6.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 72 | 115 | $57,040 | $15,926 | 27.9% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 74 | 82 | $87,494 | $15,223 | 17.4% |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | Office | 2023 | 33 | 51 | $140,862 | $15,172 | 10.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 255 | 1,141 | $73,024 | $11,765 | 16.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 305 | 1,141 | $22,820 | $9,581 | 42.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 293 | 1,251 | $45,036 | $9,493 | 21.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 87 | 164 | $51,332 | $8,341 | 16.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 64 | 149 | $51,256 | $7,889 | 15.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 37 | 115 | $28,405 | $7,048 | 24.8% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 45 | 75 | $49,275 | $6,779 | 13.8% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 118 | 524 | $56,592 | $6,521 | 11.5% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 12 | 48 | $176,400 | $6,342 | 3.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 26 | 106 | $22,366 | $6,306 | 28.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 47 | 47 | $26,555 | $5,989 | 22.6% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 17 | 4,290 | $34,320 | $5,909 | 17.2% |
About Dr. Jeffrey Yorio, MD
Dr. Jeffrey Yorio, MD is a Internal Medicine healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/11/2008. The National Provider Identifier (NPI) number assigned to this provider is 1215197314.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Yorio, MD has received a total of $15,278 in payments from pharmaceutical and medical device companies, with $1,121 received in 2024. These payments were reported across 74 transactions from 28 companies. The most common payment nature is "Consulting Fee" ($8,056).
As a Medicare-enrolled provider, Yorio has provided services to 16,453 Medicare beneficiaries, totaling 373,256 services with total Medicare billing of $4.3M. Data is available for 4 years (2020–2023), covering 333 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Student in an Organized Health Care Education/Training Program
- Location Austin, TX
- Active Since 06/11/2008
- Last Updated 11/15/2017
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1215197314
Products in Payments
- BRAFTOVI (Drug) $1,890
- ERLEADA (Drug) $1,806
- CABOMETYX (Drug) $298.95
- SARCLISA (Biological) $196.50
- FOTIVDA (Drug) $144.14
- ELIQUIS (Drug) $132.75
- Rituxan (Biological) $123.26
- IMLYGIC (Biological) $122.81
- Trodelvy (Drug) $114.78
- iDrive (Device) $96.42
- Da Vinci Surgical System (Device) $92.32
- LIBTAYO (Biological) $82.67
- PADCEV (Biological) $42.29
- RYBREVANT (Drug) $37.57
- REBLOZYL (Biological) $29.95
- LYNPARZA (Drug) $29.35
- Enhertu (Drug) $27.69
- FOUNDATIONONE CDX (Device) $26.73
- Lenvima (Drug) $24.68
- Amtagvi (Drug) $22.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Austin
Dr. Andrew Brenner, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $126,872
Internal Medicine $126,872
John Dallas, Md, MD
Internal Medicine — Payments: $94,461
Internal Medicine $94,461
Omesh Verma, Md, MD
Internal Medicine — Payments: $93,276
Internal Medicine $93,276
Lindsay Harrison, Md, MD
Internal Medicine — Payments: $80,623
Internal Medicine $80,623
Dr. Steven Berkowitz, Md, MD
Internal Medicine — Payments: $79,153
Internal Medicine $79,153
Dr. Manoj Thangam, M.d, M.D
Internal Medicine — Payments: $76,243
Internal Medicine $76,243